AI Article Synopsis
- The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score help identify multiple myeloma (MM) patients at risk for immune-related side effects and early death during cellular immunotherapy.
- A study involving 126 MM patients treated with T-cell redirecting bispecific antibodies (bsAb) assessed the impact of these scores on patient outcomes.
- While 19% of patients were deemed high risk according to GPS, they did not experience worse outcomes, but those classified as high risk by CAR-HT faced more infections and had lower survival rates, indicating the need for better infection management.
Article Abstract
The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity and early mortality with cellular immunotherapy. However, their association with outcomes in patients receiving T-cell redirecting bispecific antibodies (bsAb) is unclear. This multi-centre retrospective study examines the association of baseline GPS and CAR-HT scores with outcomes in 126 MM patients treated with bsAb. Overall, 19% were identified as GPS high risk but did not experience increased toxicity or mortality. Conversely, high-risk CAR-HT patients had a higher incidence of infections and inferior survival, suggesting a need for aggressive infection mitigation strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.19700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!